DUBLIN, Ohio--(BUSINESS WIRE)--At its first Analyst Day, Neoprobe Corporation (OTCBB: NEOP), a diversified developer of innovative oncology surgical and diagnostic products, provided analysts and investors in attendance with an in-depth update on Neoprobe’s corporate and drug pipeline developments as well insights into recent progress in cancer diagnosis and treatment.
